Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer
2025-10-01
|
| Серии: | Discover Oncology |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1007/s12672-025-03569-x |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|